Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

DayOne Experts - Next generation clinical trials

439 views

Published on

Event introduction slides by Thomas Brenzikofer.
Read the event report here:https://www.baselarea.swiss/baselarea-swiss/channels/innovation-report/2019/06/on-the-verge-of-being-born-next-generation-clinical-trials.html

Tomasz Sablinski, Founder and CEO of Transparency Life Sciences raised the crunch question of the evening: Which industry is lagging behind the most in terms of digitization? Right, it is the healthcare industry! But who would have expected the usual lamentation of why this is the case; blaming regulatory constraints, scarce innovation culture, or unachievable technology barriers proved wrong. The appetite for change and finding new ways of doing things was too strong among Basel’s Healthcare innovators at the DayOne Expert Session on “Next Generation Digital Trials”.
The idea of the event was to present a holistic view of the current standing in the digitizing clinical trials.

Published in: Healthcare
  • Be the first to comment

  • Be the first to like this

DayOne Experts - Next generation clinical trials

  1. 1. DayOne Core Team Experts from across industry and stakeholders Michael Rebhan, Novartis Peter Groenen, Idorsia Alain Bindels, Roche Frank Kumli, Ernst & Young Torsten Schwede, University of Basel and Swiss Institute of Bioinformatics Andreas Wicki, University Hospital Basel Erik Schkommodau, University of Applied Science and Arts Northwestern Switzerland Christian Bosshard, CSEM Laurenz Baltzer, KARGER Bram Stieltjes, University Hospital Basel André Moeri, Medgate Bhupinder Bhullar, Consultant Douglas Haggstrom, Consultant Thomas Brenzikofer, BaselArea.swiss Fabian Streiff, Department of Economic, Social and Environmental Affairs of the Canton of Basel-Stadt DayOne Experts – 25.6.2019 DayOne Experts: next generation clinical trials
  2. 2. Thomas Brenzikofer, BaselArea.swiss, Co-Founder DayOne DayOne Creating a world-leading hub for healthcare innovation in precision medicine and digital health
  3. 3. the leading hub for healthcare innovation in precision medicine
  4. 4. A growing community of healthcare innovators 1500 professionals, entrepreneurs, researchers across all disciplines
  5. 5. DayOne Core Team Experts from across industry and stakeholders Michael Rebhan, Novartis Peter Groenen, Idorsia Alain Bindels, Roche Torsten Schwede, University of Basel and Swiss Institute of Bioinformatics Christian Elias Schneider, University of Basel Andreas Wicki, Bram Stieltjes University Hospital Basel Nicole Probst-Hensch, Melissa Penny, Swiss TPH Erik Schkommodau, Enkelejda Miho, University of Applied Science and Arts FHNW Christian Bosshard, CSEM Laurenz Baltzer, KARGER André Moeri, Medgate Management Team: Bhupinder Bhullar, Douglas Haggstrom, Viktor Bullain, Bejal Joshi, Consultants Frank Kumli, Fabian Streiff, Thomas Brenzikofer, BaselArea.swiss
  6. 6. DayOne Partners Public and Industry INITIATED AND OPERATED BY IN CLOSE COLLABORATION WITH KNOWLEDGE PARTNERS SUPPORTING PARTNERS
  7. 7. DayOne Mission Create a world leading hub for healthcare innovation, built on the strength of the Basel region respected for its impact facilitating collaboration across disciplines and industries with a focus on precision medicine – the convergence of diagnostics, treatment and digital health
  8. 8. Digitisation and Precision Medicine Putting the Patient in the middle
  9. 9. The new paradigm Patient centric innovation initial failed product reservoir redefined patient population patient in the middle product proposal product prototype revised product repositioned product medicalneed problem statement refined product proposal product experience redefine product testinvent implement innovate 9
  10. 10. Implement Innovate Improve Invent Test Collaboration is key Neutral Plattform to explore ideas and setup projects 1 0
  11. 11. Implement Innovate Improve Invent Test Innovation hub as a neutral Platform Different activities reinforcing each other
  12. 12. DayOne Core Team Experts from across industry and stakeholders Michael Rebhan, Novartis Peter Groenen, Idorsia Alain Bindels, Roche Frank Kumli, Ernst & Young Torsten Schwede, University of Basel and Swiss Institute of Bioinformatics Andreas Wicki, University Hospital Basel Erik Schkommodau, University of Applied Science and Arts Northwestern Switzerland Christian Bosshard, CSEM Laurenz Baltzer, KARGER Bram Stieltjes, University Hospital Basel André Moeri, Medgate Bhupinder Bhullar, Consultant Douglas Haggstrom, Consultant Thomas Brenzikofer, BaselArea.swiss Fabian Streiff, Department of Economic, Social and Environmental Affairs of the Canton of Basel-Stadt DayOne Experts – 25.6.2019 DayOne Experts: next generation clinical trials
  13. 13. disrupting clinical trials Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/© Time Phase 1 Phase 2 Phase 3 Phase 4 20 – 80 participant 100 – 300 participant 1000 – 3000 participant > 3000 participant several month Up to 2 years Up to 4 years 1 year safety efficacy Safety, efficacy, dosing Longterm Effectiveness + cost effectiveness 33 percent Success rate 70 percent Success rate 25-30 percent Success rate 70-90 percent Success rate
  14. 14. faster patient recruitment Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/© Time Phase 1 Phase 2 Phase 3 Phase 4 20 – 80 participant 100 – 300 participant 1000 – 3000 participant > 3000 participant several month Up to 2 years Up to 4 years 1 year safety efficacy Safety, efficacy, dosing Longterm Effectiveness + cost effectiveness 33 percent Success rate 70 percent Success rate 25-30 percent Success rate 70-90 percent Success rate
  15. 15. self reporting Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/© Time Phase 1 Phase 2 Phase 3 Phase 4 20 – 80 participant 100 – 300 participant 1000 – 3000 participant > 3000 participant several month Up to 2 years Up to 4 years 1 year safety efficacy Safety, efficacy, dosing Longterm Effectiveness + cost effectiveness 33 percent Success rate 70 percent Success rate 25-30 percent Success rate 70-90 percent Success rate
  16. 16. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/© Time Phase 1 Phase 2 Phase 3 Phase 4 20 – 80 participant 100 – 300 participant 1000 – 3000 participant > 3000 participant several month Up to 2 years Up to 4 years 1 year safety efficacy Safety, efficacy, dosing Longterm Effectiveness + cost effectiveness 33 percent Success rate 70 percent Success rate 25-30 percent Success rate 70-90 percent Success rate more data
  17. 17. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/© Time Phase 1 Phase 2 Phase 3 Phase 4 20 – 80 participant 100 – 300 participant 1000 – 3000 participant > 3000 participant several month Up to 2 years Up to 4 years 1 year safety efficacy Safety, efficacy, dosing Longterm Effectiveness + cost effectiveness 33 percent Success rate 70 percent Success rate 25-30 percent Success rate 70-90 percent Success rate Better patient experience
  18. 18. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/© Time complete new way…?
  19. 19. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/© Time complete new way…?
  20. 20. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/© Time complete new way…?
  21. 21. Source: https://www.technology<eview.com/s/609647/google-has-released-an-ai-tool-that-makes-sense-of-your-genome/© Time open, virtual trials complete new way…?
  22. 22. 3 questions how can we make clinical trials more efficient, improve outcomes, providing better patient experience? to what extend will the digital tools (re)open up new fields of R&D? will this lead to new ways of doing clinical research?
  23. 23. DayOne Core Team Experts from across industry and stakeholders Michael Rebhan, Novartis Peter Groenen, Idorsia Alain Bindels, Roche Frank Kumli, Ernst & Young Torsten Schwede, University of Basel and Swiss Institute of Bioinformatics Andreas Wicki, University Hospital Basel Erik Schkommodau, University of Applied Science and Arts Northwestern Switzerland Christian Bosshard, CSEM Laurenz Baltzer, KARGER Bram Stieltjes, University Hospital Basel André Moeri, Medgate Bhupinder Bhullar, Consultant Douglas Haggstrom, Consultant Thomas Brenzikofer, BaselArea.swiss Fabian Streiff, Department of Economic, Social and Environmental Affairs of the Canton of Basel-Stadt 18:45 Welcome and introduction: Thomas Brenzkofer 19:00 Input Speeches and Panel Discussion Stijn Rogiers, SAS Lars G. Hemkens, University Hospital Basel Tomasz Sablinski, Transparency Life Sciences Catherine Wu, Roche Randy Ramin-Wright, Clinerion 20:30 closing remarks followed by networking apero
  24. 24. Next Events – save the dates! dayOne acceleration – 31. July dayOne conference – 9. September new approaches in patient centricity – 30. October future business models – 3. December
  25. 25. thomas.brenzikofer@baselarea.swiss CONTACT the leading hub for healthcare innovation in precision medicine
  26. 26. www.dayone.swiss #dayonebasel LinkedIn Groups: „DayOne – Innovation Hub for Precision Medicine“

×